BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 26771813)

  • 1. Significance of KIT exon 17 mutation depends on mutant level rather than positivity in core-binding factor acute myeloid leukemia.
    Jang W; Yoon JH; Park J; Lee GD; Kim J; Kwon A; Choi H; Han K; Nahm CH; Kim HJ; Min WS; Kim M; Kim Y
    Blood Cancer J; 2016 Jan; 6(1):e387. PubMed ID: 26771813
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The importance of relative mutant level for evaluating impact on outcome of KIT, FLT3 and CBL mutations in core-binding factor acute myeloid leukemia.
    Allen C; Hills RK; Lamb K; Evans C; Tinsley S; Sellar R; O'Brien M; Yin JL; Burnett AK; Linch DC; Gale RE
    Leukemia; 2013 Sep; 27(9):1891-901. PubMed ID: 23783394
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Core binding factor acute myeloid leukaemia and c-KIT mutations.
    Riera L; Marmont F; Toppino D; Frairia C; Sismondi F; Audisio E; Di Bello C; D'Ardia S; Di Celle PF; Messa E; Inghirami G; Vitolo U; Pich A
    Oncol Rep; 2013 May; 29(5):1867-72. PubMed ID: 23467883
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Monitoring of clonal evolution of double C-KIT exon 17 mutations by Droplet Digital PCR in patients with core-binding factor acute myeloid leukemia.
    Tan Y; Liu Z; Wang W; Zhu G; Guo J; Chen X; Zheng C; Xu Z; Chang J; Ren F; Wang H
    Leuk Res; 2018 Jun; 69():89-93. PubMed ID: 29705537
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic impact of c-KIT mutations in core binding factor acute myeloid leukemia.
    Park SH; Chi HS; Min SK; Park BG; Jang S; Park CJ
    Leuk Res; 2011 Oct; 35(10):1376-83. PubMed ID: 21715005
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Importance of c-kit mutation detection method sensitivity in prognostic analyses of t(8;21)(q22;q22) acute myeloid leukemia.
    Wakita S; Yamaguchi H; Miyake K; Mitamura Y; Kosaka F; Dan K; Inokuchi K
    Leukemia; 2011 Sep; 25(9):1423-32. PubMed ID: 21606963
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prevalence and prognostic significance of c-KIT mutations in core binding factor acute myeloid leukemia: a comprehensive large-scale study from a single Chinese center.
    Qin YZ; Zhu HH; Jiang Q; Jiang H; Zhang LP; Xu LP; Wang Y; Liu YR; Lai YY; Shi HX; Jiang B; Huang XJ
    Leuk Res; 2014 Dec; 38(12):1435-40. PubMed ID: 25449688
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Analysis of tyrosine kinases gene mutations in core binding factor related acute myeloid leukemia and its clinical significance].
    Qiao M; Li WY; Sun AN; Chen SN; Liang JY; Ding ZX; Feng YF; Wu DP
    Zhonghua Xue Ye Xue Za Zhi; 2011 Oct; 32(10):679-83. PubMed ID: 22339826
    [TBL] [Abstract][Full Text] [Related]  

  • 9. KIT D816 mutation associates with adverse outcomes in core binding factor acute myeloid leukemia, especially in the subgroup with RUNX1/RUNX1T1 rearrangement.
    Kim HJ; Ahn HK; Jung CW; Moon JH; Park CH; Lee KO; Kim SH; Kim YK; Kim HJ; Sohn SK; Kim SH; Lee WS; Kim KH; Mun YC; Kim H; Park J; Min WS; Kim HJ; Kim DH;
    Ann Hematol; 2013 Jan; 92(2):163-71. PubMed ID: 23053179
    [TBL] [Abstract][Full Text] [Related]  

  • 10. KIT mutations correlate with adverse survival in children with core-binding factor acute myeloid leukemia.
    Chen X; Dou H; Wang X; Huang Y; Lu L; Bin J; Su Y; Zou L; Yu J; Bao L
    Leuk Lymphoma; 2018 Apr; 59(4):829-836. PubMed ID: 28792268
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Next-generation sequencing with a myeloid gene panel in core-binding factor AML showed KIT activation loop and TET2 mutations predictive of outcome.
    Cher CY; Leung GM; Au CH; Chan TL; Ma ES; Sim JP; Gill H; Lie AK; Liang R; Wong KF; Siu LL; Tsui CS; So CC; Wong HW; Yip SF; Lee HK; Liu HS; Lau JS; Luk TH; Lau CK; Lin SY; Kwong YL; Leung AY
    Blood Cancer J; 2016 Jul; 6(7):e442. PubMed ID: 27391574
    [TBL] [Abstract][Full Text] [Related]  

  • 12. KIT D816 mutated/CBF-negative acute myeloid leukemia: a poor-risk subtype associated with systemic mastocytosis.
    Jawhar M; Döhner K; Kreil S; Schwaab J; Shoumariyeh K; Meggendorfer M; Span LLF; Fuhrmann S; Naumann N; Horny HP; Sotlar K; Kubuschok B; von Bubnoff N; Spiekermann K; Heuser M; Metzgeroth G; Fabarius A; Klein S; Hofmann WK; Kluin-Nelemans HC; Haferlach T; Döhner H; Cross NCP; Sperr WR; Valent P; Reiter A
    Leukemia; 2019 May; 33(5):1124-1134. PubMed ID: 30635631
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Detection of NPM1, FLT3 and C-KIT mutations in acute myeloid leukemia and their prognostic analysis].
    Li L; Lyu XD; Mi RH; Ding J; Chen L; Wang Q; Yin QS; Hu JY; Fan RH; Wei XD
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2013 Jun; 21(3):601-6. PubMed ID: 23815906
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Amyloid precursor protein cooperates with c-KIT mutation/overexpression to regulate cell apoptosis in AML1-ETO-positive leukemia via the PI3K/AKT signaling pathway.
    Yu G; Yin C; Jiang L; Zheng Z; Wang Z; Wang C; Zhou H; Jiang X; Liu Q; Meng F
    Oncol Rep; 2016 Sep; 36(3):1626-32. PubMed ID: 27460334
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cooperating mutations of receptor tyrosine kinases and Ras genes in childhood core-binding factor acute myeloid leukemia and a comparative analysis on paired diagnosis and relapse samples.
    Shih LY; Liang DC; Huang CF; Chang YT; Lai CL; Lin TH; Yang CP; Hung IJ; Liu HC; Jaing TH; Wang LY; Yeh TC
    Leukemia; 2008 Feb; 22(2):303-7. PubMed ID: 17960171
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Functional Properties of
    Tarlock K; Alonzo TA; Wang YC; Gerbing RB; Ries R; Loken MR; Pardo L; Hylkema T; Joaquin J; Sarukkai L; Raimondi SC; Hirsch B; Sung L; Aplenc R; Bernstein I; Gamis AS; Meshinchi S; Pollard JA
    Clin Cancer Res; 2019 Aug; 25(16):5038-5048. PubMed ID: 31182436
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Incidence and prognostic impact of c-Kit, FLT3, and Ras gene mutations in core binding factor acute myeloid leukemia (CBF-AML).
    Boissel N; Leroy H; Brethon B; Philippe N; de Botton S; Auvrignon A; Raffoux E; Leblanc T; Thomas X; Hermine O; Quesnel B; Baruchel A; Leverger G; Dombret H; Preudhomme C; ;
    Leukemia; 2006 Jun; 20(6):965-70. PubMed ID: 16598313
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prevalence and prognostic significance of KIT mutations in pediatric patients with core binding factor AML enrolled on serial pediatric cooperative trials for de novo AML.
    Pollard JA; Alonzo TA; Gerbing RB; Ho PA; Zeng R; Ravindranath Y; Dahl G; Lacayo NJ; Becton D; Chang M; Weinstein HJ; Hirsch B; Raimondi SC; Heerema NA; Woods WG; Lange BJ; Hurwitz C; Arceci RJ; Radich JP; Bernstein ID; Heinrich MC; Meshinchi S
    Blood; 2010 Mar; 115(12):2372-9. PubMed ID: 20056794
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High expression of c-kit mRNA predicts unfavorable outcome in adult patients with t(8;21) acute myeloid leukemia.
    Gao X; Lin J; Gao L; Deng A; Lu X; Li Y; Wang L; Yu L
    PLoS One; 2015; 10(4):e0124241. PubMed ID: 25860287
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Detection of KIT and FLT3 mutations in acute myeloid leukemia with different subtypes.
    Zaker F; Mohammadzadeh M; Mohammadi M
    Arch Iran Med; 2010 Jan; 13(1):21-5. PubMed ID: 20039765
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.